[
  {
    "ts": null,
    "headline": "INCY Q2 Deep Dive: Product Launches and Pipeline Progress Underpin Revenue Growth",
    "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 16.5% year on year to $1.22 billion. Its non-GAAP profit of $1.57 per share was 6.5% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=f229afd7fbfa6e09e9f1673bfa7cc88d6852abc1b6620abfb53408090a31a6d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755058502,
      "headline": "INCY Q2 Deep Dive: Product Launches and Pipeline Progress Underpin Revenue Growth",
      "id": 136328884,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 16.5% year on year to $1.22 billion. Its non-GAAP profit of $1.57 per share was 6.5% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=f229afd7fbfa6e09e9f1673bfa7cc88d6852abc1b6620abfb53408090a31a6d5"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Incyte’s Q2 Earnings Call",
    "summary": "Incyte’s second quarter was marked by broad-based strength across its commercial portfolio, reflected in a significant positive market reaction. Management attributed the strong results to robust demand for Jakafi and Opzelura, as well as the rapid adoption of newly launched Niktimvo in bone marrow transplant centers. CEO William Meury highlighted, “Opzelura is showing strong broad-based growth today across AD and Vitiligo,” and noted Niktimvo’s swift penetration, capturing about 10% of its targ",
    "url": "https://finnhub.io/api/news?id=963057ede5e1360ae86277a3a8e23cde8987e887128937f6fe3852adc239d3f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755058255,
      "headline": "The Top 5 Analyst Questions From Incyte’s Q2 Earnings Call",
      "id": 136328885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte’s second quarter was marked by broad-based strength across its commercial portfolio, reflected in a significant positive market reaction. Management attributed the strong results to robust demand for Jakafi and Opzelura, as well as the rapid adoption of newly launched Niktimvo in bone marrow transplant centers. CEO William Meury highlighted, “Opzelura is showing strong broad-based growth today across AD and Vitiligo,” and noted Niktimvo’s swift penetration, capturing about 10% of its targ",
      "url": "https://finnhub.io/api/news?id=963057ede5e1360ae86277a3a8e23cde8987e887128937f6fe3852adc239d3f8"
    }
  }
]